Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas PharmaInvestors Business Daily • 05/01/23
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The LancetPRNewsWire • 04/14/23
CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS CellsPRNewsWire • 04/12/23
Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar®PRNewsWire • 03/29/23
Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The LancetPRNewsWire • 03/13/23
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of GilteritinibPRNewsWire • 03/09/23
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe DiseasePRNewsWire • 01/20/23
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers SymposiumPRNewsWire • 01/19/23
Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas EmissionsPRNewsWire • 01/19/23
Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to BasileaGlobeNewsWire • 01/09/23
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) CancersPRNewsWire • 12/15/22
Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity BioPRNewsWire • 12/13/22